Sponsors (2)
The bill expands and accelerates coverage of rare‑disease drug uses supported by peer‑reviewed evidence or clinical guidelines—improving timely access and lowering patient costs—while increasing public and private spending and creating risks from approving uses with more limited evidence and added administrative/oversight burdens.
Medicare Part D enrollees with rare diseases: more drug uses supported by peer‑reviewed literature or clinical guidelines will be treated as covered, lowering out‑of‑pocket costs and expanding access to treatments.
Medicaid beneficiaries, especially low‑income patients with rare conditions: an expanded 'medically accepted indication' definition means more outpatient drugs will be eligible for coverage, improving access to needed therapies.
People with rare diseases and their clinicians: expedited appeals for denials plus allowance of peer‑reviewed evidence and society/expert guidance will speed access to therapies and help align coverage with clinical judgment.
Taxpayers and federal budgets: expanding coverage for literature/guideline‑supported rare‑disease uses will likely increase Medicare and Medicaid spending, raising program costs.
State governments and Medicaid programs: broader coverage criteria and new appeals requirements will raise prescription spending and administrative burden for states.
Private insurers, employers, and enrollees: higher pharmacy benefit costs from expanded rare‑disease coverage may translate into higher premiums, cost‑management measures, or shifting costs to workers and small businesses.
Based on analysis of 2 sections of legislative text.
Adds a pathway so drugs for diseases affecting ≤200,000 people can be "medically accepted" for Medicare and Medicaid coverage when supported by peer‑reviewed literature, guidelines, or an identified expert, subject to compendia/FDA exclusions.
Expands Medicare and Medicaid rules so certain uses of drugs for rare diseases (conditions affecting 200,000 or fewer people in the U.S.) count as "medically accepted" for coverage when supported by peer‑reviewed literature, clinical guidelines, or an expert from the relevant medical society, provided the drug is not listed as “not indicated” in specified compendia or contraindicated in FDA labeling. The change applies to Medicare Part A/B items and services and Part D plan years beginning January 1, 2027, and replaces the Medicaid outpatient drug definition to incorporate the same standard. The effect is to broaden coverage for off‑label or otherwise unsupported uses for rare‑disease patients where clinical evidence or authoritative guidance exists, creating a new evidentiary pathway for coverage while preserving exclusions where compendia or FDA labeling explicitly oppose the use.
Official title: Amend titles XVIII and XIX of the Social Security Act and title XXVII of the Public Health Service Act to provide for coverage of certain drugs used in the treatment or management of a rare disease or condition, and for other purposes.
Introduced December 17, 2025 by Thomas Roland Tillis · Last progress December 17, 2025